Stop treating the meniscus as disposable tissue.
A 2026 review found 82.5% complete/partial healing after radial tear repair [1]. In 2025, pooled failure was 11.1% for inside-out vs 15.9% for all-inside repair [2]. 🦵
Why care now? Across 31,783 patients, repair was associated
ACL reconstruction is entering a new era.
In 2026, MLS surgeons reported lateral extra-articular augmentation in 31.5% of primary ACLRs and 76% of revisions. Quadriceps tendon grafts are also gaining ground, especially in revision surgery. [1][2] 🦵
This matters beyond
Shoulder arthroplasty is being reinvented in real time. 🦾
AAOS’ 2025 registry logged 53,541 procedures up 47% including 27,461 shoulder arthroplasties [1]. A 2025 study found ASC cases cost $4,600 on surgery day vs $11,100 in hospital outpatient settings, but had higher
PJI prevention just got less comfortable.
A 2026 multicenter RCT of 2,053 high-risk hip/knee arthroplasty patients found no significant 1-year PJI reduction from vancomycin powder, dilute povidone-iodine, or both vs saline [1]. 🧪
Meanwhile, Europe’s PJI burden after primary
PRP may be biologically active and clinically overhyped.
A 2026 meta-analysis of 4 RCTs (337 patients) found no PRP benefit over placebo for Achilles tendinopathy at 3 or 6 months. [1] A 2025 review found mixed evidence for PRP, BMAC and patch augmentation. [2] 🧬
Use is
